Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 463.3 DKK -1.34%
Market Cap: 33.1B DKK
Section:
 

Relative Value

The Relative Value of one ZEAL stock under the Base Case scenario is 779.06 DKK. Compared to the current market price of 463.3 DKK, Zealand Pharma A/S is Undervalued by 41%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ZEAL Relative Value
Base Case
779.06 DKK
Undervaluation 41%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.6
P/S
P/S
Price to Sales
3.6
vs History
93
vs Industry
5
Median 3Y
114
Median 5Y
56.4
Industry
7.9
Forward
3.5
More Details
5
P/E
P/E
Price to Earnings
5
vs History
4
vs Industry
Median 3Y
-22.8
Median 5Y
-9.5
Industry
23.7
Forward
5
More Details
4.4
P/OCF
P/OCF
Price to OCF
4.4
vs History
4
vs Industry
Median 3Y
-23.5
Median 5Y
-11.7
Industry
22
More Details
4.4
P/FCFE
P/FCFE
Price to FCFE
4.4
vs History
4
vs Industry
Median 3Y
-13.1
Median 5Y
-10.3
Industry
23.8
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
93
vs Industry
20
Median 3Y
8
Median 5Y
6.7
Industry
3.3
More Details
1.9
EV/S
EV/S
Enterprise Value to Sales
1.9
vs History
93
vs Industry
5
Median 3Y
105.7
Median 5Y
51.7
Industry
8.3
Forward
1.8
More Details
1.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.9
vs History
84
vs Industry
3
Median 3Y
88.5
Median 5Y
51.9
Industry
10.1
More Details
2.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
2.3
vs History
4
vs Industry
Median 3Y
-18
Median 5Y
-12.4
Industry
6.4
Forward
2.4
More Details
2.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
2.3
vs History
4
vs Industry
Median 3Y
-17.7
Median 5Y
-11.5
Industry
7
Forward
2.4
More Details
2.3
EV/OCF
EV/OCF
Enterprise Value to OCF
2.3
vs History
4
vs Industry
Median 3Y
-20.5
Median 5Y
-10.5
Industry
8.3
More Details
2.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
2.3
vs History
4
vs Industry
Median 3Y
-20.2
Median 5Y
-10.4
Industry
6.5
More Details
44.3
EV/IC
EV/IC
Enterprise Value to IC
44.3
vs History
47
vs Industry
8
Median 3Y
54.5
Median 5Y
45.5
Industry
5.7
More Details

Multiples Across Competitors

ZEAL Competitors Multiples
Zealand Pharma A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Zealand Pharma A/S
CSE:ZEAL
32.8B DKK 3.6 5 2.3 2.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 770 229.5 -160 504.9 -194 904.1 -192 680.1
US
Abbvie Inc
NYSE:ABBV
395.3B USD 6.6 168.4 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
175.8B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
147.5B USD 5.1 18.2 12.2 12.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.1 -532.3 -579.6 -564.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.5 12.5 15.6
NL
argenx SE
XBRU:ARGX
45.1B EUR 14.7 34.6 59.6 61.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 183.4 155.3 188.4
P/E Multiple
Earnings Growth PEG
DK
Zealand Pharma A/S
CSE:ZEAL
Average P/E: 166.9
5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 504.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
NL
argenx SE
XBRU:ARGX
34.6
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 183.4
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBITDA: 35.1
2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 904.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
7%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
59.6
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.3
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
Zealand Pharma A/S
CSE:ZEAL
Average EV/EBIT: 40.4
2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 680.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
NL
argenx SE
XBRU:ARGX
61.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.4
N/A N/A

See Also

Summary
ZEAL intrinsic value, competitors valuation, and company profile.
DCF Valuation
ZEAL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ZEAL stock valuation using valuation multiples.
Wall Street Estimates
ZEAL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ZEAL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.